Lyndra Therapeutics, Inc.


Lyndra Therapeutics is dedicated to reinventing medicine through innovative long-acting oral therapies. Their proprietary LYNX™ drug delivery platform aims to deliver medicine for a week or longer in an oral form, significantly improving medication adherence and patient experience. The company was founded in 2015, emerging from technology developed at MIT, and has achieved rapid progress with multiple therapies in development across various therapeutic areas. Lyndra's culture emphasizes diversity, inclusion, innovation, and a mission to create game-changing treatments for a healthier world.

Industries

biotechnology
clinical-trials
health-care
pharmaceutical

Nr. of Employees

medium (51-250)

Lyndra Therapeutics, Inc.

Watertown, Massachusetts, United States, North America


Products

Long-acting oral drug delivery platform

A capsule-based oral delivery platform designed to release medication over days to weeks from a single dose, compatible with multiple small-molecule APIs and intended to improve adherence and enable weekly or monthly oral dosing.


Services

Partnerships for platform licensing and development

Collaborative development and partnership opportunities to apply the long-acting oral delivery platform to partner APIs and programs, including public-health collaborations.

GMP manufacturing and commercial manufacturing services

In-house GMP manufacturing capability for clinical and commercial production of long-acting oral dosage forms, and collaborations for commercial manufacturing scale-up.

Clinical development and trial execution for long-acting oral therapies

Design and conduct of clinical trials including early-stage PK/safety studies and pivotal efficacy trials for oral long-acting formulations.

Expertise Areas

  • Long-acting oral drug delivery
  • Gastroretentive and controlled-release formulation
  • Formulation development and multi-API co-formulation
  • Clinical trial management for oral dosage forms (Phase 1–3)
  • Show More (6)

Key Technologies

  • Gastroretentive oral dosage design
  • Controlled-release oral formulation
  • Multi-API co-formulation
  • Pharmacokinetic characterization
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.